Published On: Sun, Mar 27th, 2016

Cannabis Science (OTC: CBIS) in Negotiations for Major Drug Development Deal

On the heels of the announcement that Cannabis Science, Inc. (OTC: CBIS) is in negotiationson a majordrug development program, shares surged to close up 20% on Friday’s trading session. The company stated their negotiations centered around a 360,000 square foot, fully licensed cannabinoid grow area with a separate formulation and processing area in the state of Nevada. The company seems optimistic that this will allow them to bring new drugs from concept to dispensary shelves much more quickly, and it would easily increase output capacity for production-level products at the same time.

The more central location for these facilities will allow the country to distribute product to markets outside of the West Coast more easily. As an increasing amount of states across the country bring forth legislation to allow residents to use medicinal and/or recreational cannabis, a wider-reaching distribution network becomes more and more important. The company is proactively working to meet demand forecasts in markets that could open up in the near future. In addition to this opportunity in Nevada, the company continues to improve its foundation in California as well.

With the added capacity the new facilities could provide, the company intends to move forward more quickly with its trials and manufacturing of treatments for cancer, PTSD, HIV/AIDS, autism, and other neurological disorders. This could allow the company to commercialize new treatments at a much higher rate than many competitors, which leads to a sound market advantage due to the added responsiveness to the ever-changing demands of the pharmaceutical industry.

© Copyright 2016 OTC News Magazine. All rights reserved.